Tevogen Inc.
For the period ended Dec 31, 2024. Filed Apr 2, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 2, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized**.**
| Tevogen Bio Holdings Inc. | ||
| Date: April 2, 2025 | By: | /s/ Ryan Saadi |
|---|---|---|
| Ryan Saadi | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Date | Title |
|---|---|---|
| /s/ Ryan Saadi | April 2, 2025 | Chief Executive Officer and Chairperson of the Board of Directors |
| Ryan Saadi | (Principal Executive Officer) | |
| /s/ Kirti Desai | April 2, 2025 | Chief Financial Officer |
| Kirti Desai | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Jeffrey Feike | April 2, 2025 | Director |
| Jeffrey Feike | ||
| /s/ Dr. Keow Lin Goh | April 2, 2025 | Director |
| Dr. Keow Lin Goh | ||
| /s/ Dr. Curtis Patton | April 2, 2025 | Director |
| Dr. Curtis Patton | ||
| /s/ Susan Podlogar | April 2, 2025 | Director |
| Susan Podlogar | ||
| /s/ Victor Sordillo | April 2, 2025 | Director |
| Victor Sordillo | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.